Adamis Pharmaceuticals (ADMP) Getting Positive Press Coverage, Report Finds
News articles about Adamis Pharmaceuticals (NASDAQ:ADMP) have trended positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a news sentiment score of 0.26 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 44.9253777403929 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- Adamis Pharmaceuticals Corporation, (NASDAQ: ADMP) – Do Investors Want To Take Risk on This Stock – Stock Watch (stocksnewstimes.com)
- Critical Review: Adamis Pharmaceuticals (ADMP) versus Amgen (AMGN) (americanbankingnews.com)
- Novartis (NVS) & Adamis Pharmaceuticals (ADMP) Head-To-Head Survey (americanbankingnews.com)
- Prominent Runners: Harmonic Inc. (NASDAQ:HLIT), Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – The Oracle Examiner (oracleexaminer.com)
- Hot Stock under Consideration – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) – Alpha Beta Stock (alphabetastock.com)
A number of research analysts have issued reports on the company. Maxim Group set a $14.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. B. Riley set a $10.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 30th. ValuEngine cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $10.33.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.